Gyre reports Q2 2026 results, advances F351 NDA and Cullgen pipelineAug 7Quarterly updateGyre Therapeutics, Inc.
Gyre Therapeutics adds three directors to board effective August 1, 2026Jul 16PeopleGyre Therapeutics, Inc.
Cullgen discloses 2025 results and merger deal with Gyre TherapeuticsJul 15Quarterly updateGyre Therapeutics, Inc.
Sign inSign in